[go: up one dir, main page]

SG46632A1 - Novel process for the preparation of cetrorelix lyophilisate - Google Patents

Novel process for the preparation of cetrorelix lyophilisate

Info

Publication number
SG46632A1
SG46632A1 SG1996006874A SG1996006874A SG46632A1 SG 46632 A1 SG46632 A1 SG 46632A1 SG 1996006874 A SG1996006874 A SG 1996006874A SG 1996006874 A SG1996006874 A SG 1996006874A SG 46632 A1 SG46632 A1 SG 46632A1
Authority
SG
Singapore
Prior art keywords
dried
sterile freeze
cetrorelix
cetrorelix acetate
preparation
Prior art date
Application number
SG1996006874A
Other languages
English (en)
Inventor
Dieter Sauerbier
Burkhard Wichert
Thomas Reissmann
Jurgen Engel
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6480924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG46632(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of SG46632A1 publication Critical patent/SG46632A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
SG1996006874A 1993-02-19 1994-02-04 Novel process for the preparation of cetrorelix lyophilisate SG46632A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4305225A DE4305225A1 (de) 1993-02-19 1993-02-19 Neues Herstellverfahren für Cetrorelix Lyophilisat

Publications (1)

Publication Number Publication Date
SG46632A1 true SG46632A1 (en) 1998-02-20

Family

ID=6480924

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996006874A SG46632A1 (en) 1993-02-19 1994-02-04 Novel process for the preparation of cetrorelix lyophilisate

Country Status (29)

Country Link
EP (2) EP0947200B1 (zh)
JP (1) JP4033919B2 (zh)
KR (2) KR100355686B1 (zh)
CN (1) CN1109557C (zh)
AT (1) ATE193653T1 (zh)
AU (1) AU671881C (zh)
BR (1) BR9400617A (zh)
CA (1) CA2115943C (zh)
CZ (2) CZ285768B6 (zh)
DE (2) DE4305225A1 (zh)
DK (1) DK0611572T3 (zh)
ES (1) ES2148247T3 (zh)
FI (1) FI110059B (zh)
GR (1) GR3034237T3 (zh)
HR (1) HRP940117B1 (zh)
HU (1) HU218281B (zh)
IL (1) IL108704A (zh)
MX (1) MX9401312A (zh)
NO (1) NO316601B1 (zh)
NZ (2) NZ250906A (zh)
PL (1) PL177177B1 (zh)
PT (1) PT611572E (zh)
RU (1) RU2145234C1 (zh)
SG (1) SG46632A1 (zh)
SI (1) SI9400087B (zh)
SK (2) SK283021B6 (zh)
TW (1) TW387812B (zh)
UA (1) UA43829C2 (zh)
ZA (1) ZA941136B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
HU228736B1 (en) * 1998-04-23 2013-05-28 Zentaris Ivf Gmbh Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
DK1565160T3 (da) 2002-09-27 2014-04-28 Terna Zentaris Gmbh Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
CN101629758B (zh) * 2008-07-19 2012-09-26 浙江家泰电器制造有限公司 液体加热器皿过热保护控制器组件
CN101630607B (zh) * 2008-07-19 2012-04-25 浙江家泰电器制造有限公司 液体加热器皿过热保护控制器组件
RU2454221C2 (ru) * 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Способ получения лиофилизированного противовирусного средства
EP2648755A1 (en) 2010-12-06 2013-10-16 Astron Research Limited A stable ready-to-use cetrorelix injection
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102423484B (zh) * 2011-11-23 2014-01-15 深圳翰宇药业股份有限公司 一种稳定的西曲瑞克药物组合物及其制备方法
EP3015553A1 (de) 2014-10-30 2016-05-04 Biotecon Diagnostics GmbH Stabilisierte Reaktionsmischung
RU2667128C2 (ru) 2016-12-29 2018-09-14 Герман Петрович Беккер Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе
WO2020254952A1 (en) 2019-06-17 2020-12-24 Intas Pharmaceuticals Ltd. A stable formulation of cetrorelix
CN112717119B (zh) * 2021-01-27 2024-04-30 南京羚诺生物医药技术研究院有限公司 一种西曲瑞克药物组合物及其制备方法
US20240123021A1 (en) 2021-06-25 2024-04-18 Extrovis Ag Pharmaceutical compositions
CN114159544A (zh) * 2022-01-24 2022-03-11 福州华为医药技术开发有限公司 注射用醋酸西曲瑞克及其制备方法
CN115969954A (zh) * 2023-01-09 2023-04-18 开封明仁药业有限公司 一种注射用西曲瑞克冻干药物组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816386A (en) * 1972-06-20 1974-06-11 Abbott Lab Purification process for gn-rh
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
CS230614B1 (en) * 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
EP0268066A3 (en) * 1986-10-17 1990-07-11 Syntex (U.S.A.) Inc. Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
DE3735614A1 (de) * 1986-10-31 1988-07-28 Asta Pharma Ag Ifosfamid-lyophilisat und verfahren zu dessen herstellung
DK49987A (da) * 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
FR2635006B1 (fr) * 1988-08-02 1990-10-19 Letourneur Bernard Medicament destine a regulariser les secretions hormonales et a traiter la sterilite
US5180711A (en) * 1990-06-14 1993-01-19 Applied Research Systems Ars Holding N.V. Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (zh) * 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法

Also Published As

Publication number Publication date
NZ314707A (en) 1999-02-25
RU2145234C1 (ru) 2000-02-10
HUT67117A (en) 1995-02-28
CA2115943C (en) 2003-08-05
ATE193653T1 (de) 2000-06-15
IL108704A (en) 2005-05-17
CN1109557C (zh) 2003-05-28
DE4305225A1 (de) 1994-08-25
HU218281B (en) 2000-07-28
IL108704A0 (en) 1994-05-30
AU671881C (en) 2004-01-15
HRP940117B1 (en) 2001-02-28
SK283022B6 (sk) 2003-02-04
NO940564L (zh) 1994-08-22
TW387812B (en) 2000-04-21
CN1112019A (zh) 1995-11-22
NZ250906A (en) 1997-07-27
MX9401312A (es) 1994-08-31
AU5523594A (en) 1994-08-25
CA2115943A1 (en) 1994-08-20
SK19594A3 (en) 1994-09-07
CZ31294A3 (en) 1994-09-14
DK0611572T3 (da) 2000-09-25
PT611572E (pt) 2000-11-30
UA43829C2 (uk) 2002-01-15
BR9400617A (pt) 1994-09-27
FI940779A0 (fi) 1994-02-18
KR100355686B1 (ko) 2002-12-11
SI9400087A (en) 1994-12-31
CZ285768B6 (cs) 1999-11-17
ES2148247T3 (es) 2000-10-16
JP4033919B2 (ja) 2008-01-16
EP0611572B1 (de) 2000-06-07
CZ284314B6 (cs) 1998-10-14
AU671881B2 (en) 1996-09-12
EP0611572A2 (de) 1994-08-24
JPH06271476A (ja) 1994-09-27
DE59409389D1 (de) 2000-07-13
FI110059B (fi) 2002-11-29
SK283021B6 (sk) 2003-02-04
EP0947200A2 (de) 1999-10-06
HRP940117A2 (en) 1996-08-31
NO316601B1 (no) 2004-03-08
EP0611572A3 (de) 1995-01-11
FI940779L (fi) 1994-08-20
HU9400481D0 (en) 1994-12-28
SI9400087B (sl) 2002-02-28
GR3034237T3 (en) 2000-12-29
NO940564D0 (no) 1994-02-18
KR100372187B1 (ko) 2003-02-14
EP0947200B1 (de) 2015-03-11
EP0947200A3 (de) 2004-03-24
PL177177B1 (pl) 1999-10-29
ZA941136B (en) 1994-08-29

Similar Documents

Publication Publication Date Title
SG46632A1 (en) Novel process for the preparation of cetrorelix lyophilisate
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
CA2131168A1 (en) Decontaminating blood components
CA2028140A1 (en) Novel bacteriocin compositions for use as enhanced broad range
DE69131200D1 (en) Herpes simplex virus vp16 impfstoffe
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
NZ506631A (en) Formulations for the stabilisation of PEG-interferon alpha conjugates during and after lyophilization
ZA947894B (en) Compounds for medicinal use
CA2025070A1 (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof
AU1290288A (en) A process for treating infertility and an agent for use in the process
CA2042934A1 (en) Treatment of ocular hypertension with an ocular synergistic combination
MY110998A (en) Antibiotic combination
CA2133441A1 (en) Haemophilus somnus immunogenic proteins
EP0342015A3 (en) Peptides, their use and pharmaceutical compositions containing them
IT1255649B (it) Peptidi dotati di attivita' antibatterica
MY111630A (en) Amino acid derivatives.
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
CO4700451A1 (es) Dimaleato de n,n-dietil-8, 8-dipropil-2-azaspiro[4.5] decano-2-propanamina
NZ331674A (en) Use of antigenic preparations comprising Helicobacter catalase for treating or preventing Helicobacter infection